Castle Biosciences INC 10-Q quarterly reports

Castle Biosciences reports Q2 2026 results with revenue growth driven by non-dermatologic tests, though net loss widens.

Castle Biosciences reported a net loss of $0.5 million in Q3 2025, a significant decline from a $2.3 million net income in Q3 2024, primarily due to a decrease in dermatologic test revenue and increased operating expenses, despite strong growth in non-dermatologic tests.

Castle Biosciences reported a net loss for the six months ended June 30, 2025, driven by the discontinuation of its IDgenetix test and loss of Medicare coverage for DecisionDx-SCC, despite overall revenue growth.

Castle Biosciences saw a revenue increase in Q1 2025, but a larger net loss due to the discontinuation of its IDgenetix test and related amortization expenses.

Castle Biosciences reports a strong third quarter in 2024, achieving profitability with significant revenue growth driven by both dermatologic and non-dermatologic testing segments.

Castle Biosciences experienced a significant increase in revenue and a return to profitability in the second quarter of 2024, driven by strong performance in both dermatologic and non-dermatologic testing segments.

Castle Biosciences saw a significant 73.6% increase in revenue in the first quarter of 2024 compared to the same period last year, driven by growth in both dermatologic and non-dermatologic testing.